FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2119886876> ?p ?o ?g. }

• W2119886876 endingPage "87" @default.
• W2119886876 startingPage "79" @default.
• W2119886876 abstract "BackgroundA prospective randomized clinical trial was implemented to assess whether the concomitant or the sequential addition of tamoxifen to chemotherapy provides improved clinical benefit in the adjuvant treatment of breast cancer in postmenopausal patients.Patients and methodsFour-hundred and eighty-five patients with node-positive operable disease were randomized to receive tamoxifen (20 mg/day) concomitantly (CON) or sequentially (SEQ) to EC chemotherapy (epirubicin 75 mg/m2 + cyclophosphamide 600 mg/m2 on day 1, every 21 days for four cycles).ResultsIn the 474 fully evaluable patients there were 96 events; eight being second neoplasms and 88 being related to the breast cancer. Of these, 48 of 88 occurred in the CON arm and 40 of 88 in the SEQ arm. The Kaplan–Meier estimation of disease-free survival (DFS) at 5 years was 70% in the CON and 75% in the SEQ group (log-rank test, P = 0.43). Adjusted hazard ratio for treatment was 1.11 (95% confidence interval 0.71–1.73; P = 0.64).ConclusionThis study fails to show an advantage of one treatment arm over the other, but a trend, albeitnon-significant, appears to favor the sequential addition of tamoxifen to epirubicin + cyclophosphamide and, as such, warrants further investigation." @default.
• W2119886876 created "2016-06-24" @default.
• W2119886876 creator A5018539798 @default.
• W2119886876 creator A5024472410 @default.
• W2119886876 creator A5034457114 @default.
• W2119886876 creator A5035054317 @default.
• W2119886876 creator A5036532311 @default.
• W2119886876 creator A5040158829 @default.
• W2119886876 creator A5043145360 @default.
• W2119886876 creator A5044300402 @default.
• W2119886876 creator A5045378192 @default.
• W2119886876 creator A5046817193 @default.
• W2119886876 creator A5049485209 @default.
• W2119886876 creator A5066030426 @default.
• W2119886876 creator A5071202334 @default.
• W2119886876 creator A5073061237 @default.
• W2119886876 creator A5073256515 @default.
• W2119886876 creator A5075417962 @default.
• W2119886876 creator A5078161203 @default.
• W2119886876 creator A5079628452 @default.
• W2119886876 creator A5081837484 @default.
• W2119886876 creator A5085653177 @default.
• W2119886876 date "2004-01-01" @default.
• W2119886876 modified "2023-10-18" @default.
• W2119886876 title "Epirubicin–cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study" @default.
• W2119886876 cites W1562190372 @default.
• W2119886876 cites W1835742705 @default.
• W2119886876 cites W1991405533 @default.
• W2119886876 cites W2011135202 @default.
• W2119886876 cites W2013256551 @default.
• W2119886876 cites W2030343378 @default.
• W2119886876 cites W2052761781 @default.
• W2119886876 cites W206480088 @default.
• W2119886876 cites W2075930631 @default.
• W2119886876 cites W2128069055 @default.
• W2119886876 cites W2133347950 @default.
• W2119886876 cites W2141647078 @default.
• W2119886876 cites W2165254830 @default.
• W2119886876 cites W2179930767 @default.
• W2119886876 cites W2183288147 @default.
• W2119886876 cites W2218177752 @default.
• W2119886876 cites W2227853740 @default.
• W2119886876 cites W2228075402 @default.
• W2119886876 cites W2263907628 @default.
• W2119886876 cites W2314635417 @default.
• W2119886876 cites W2329949221 @default.
• W2119886876 cites W4245415106 @default.
• W2119886876 cites W4302894403 @default.
• W2119886876 doi "https://doi.org/10.1093/annonc/mdh016" @default.
• W2119886876 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14679124" @default.
• W2119886876 hasPublicationYear "2004" @default.
• W2119886876 type Work @default.
• W2119886876 sameAs 2119886876 @default.
• W2119886876 citedByCount "67" @default.
• W2119886876 countsByYear W21198868762012 @default.
• W2119886876 countsByYear W21198868762013 @default.
• W2119886876 countsByYear W21198868762014 @default.
• W2119886876 countsByYear W21198868762015 @default.
• W2119886876 countsByYear W21198868762016 @default.
• W2119886876 countsByYear W21198868762017 @default.
• W2119886876 countsByYear W21198868762018 @default.
• W2119886876 countsByYear W21198868762019 @default.
• W2119886876 countsByYear W21198868762020 @default.
• W2119886876 countsByYear W21198868762022 @default.
• W2119886876 countsByYear W21198868762023 @default.
• W2119886876 crossrefType "journal-article" @default.
• W2119886876 hasAuthorship W2119886876A5018539798 @default.
• W2119886876 hasAuthorship W2119886876A5024472410 @default.
• W2119886876 hasAuthorship W2119886876A5034457114 @default.
• W2119886876 hasAuthorship W2119886876A5035054317 @default.
• W2119886876 hasAuthorship W2119886876A5036532311 @default.
• W2119886876 hasAuthorship W2119886876A5040158829 @default.
• W2119886876 hasAuthorship W2119886876A5043145360 @default.
• W2119886876 hasAuthorship W2119886876A5044300402 @default.
• W2119886876 hasAuthorship W2119886876A5045378192 @default.
• W2119886876 hasAuthorship W2119886876A5046817193 @default.
• W2119886876 hasAuthorship W2119886876A5049485209 @default.
• W2119886876 hasAuthorship W2119886876A5066030426 @default.
• W2119886876 hasAuthorship W2119886876A5071202334 @default.
• W2119886876 hasAuthorship W2119886876A5073061237 @default.
• W2119886876 hasAuthorship W2119886876A5073256515 @default.
• W2119886876 hasAuthorship W2119886876A5075417962 @default.
• W2119886876 hasAuthorship W2119886876A5078161203 @default.
• W2119886876 hasAuthorship W2119886876A5079628452 @default.
• W2119886876 hasAuthorship W2119886876A5081837484 @default.
• W2119886876 hasAuthorship W2119886876A5085653177 @default.
• W2119886876 hasBestOaLocation W21198868761 @default.
• W2119886876 hasConcept C121608353 @default.
• W2119886876 hasConcept C126322002 @default.
• W2119886876 hasConcept C143998085 @default.
• W2119886876 hasConcept C168563851 @default.
• W2119886876 hasConcept C207103383 @default.
• W2119886876 hasConcept C2776694085 @default.
• W2119886876 hasConcept C2776755627 @default.
• W2119886876 hasConcept C2777176818 @default.
• W2119886876 hasConcept C2779384505 @default.
• W2119886876 hasConcept C2780835546 @default.
• W2119886876 hasConcept C44249647 @default.

• next